Peritoneal Carcinomatosis in Colorectal Cancer: Review and Update of Current Clinical Data

IF 3.3 3区医学 Q2 ONCOLOGY

Clinical colorectal cancer Pub Date : 2024-05-21 DOI:10.1016/j.clcc.2024.05.007

S. Blaj , H. Leebmann , M. Babucke , M. Acs , P. Piso

引用次数: 0

Abstract

The peritoneal metastasized colorectal cancer (pmCRC) represents a serious health problem worldwide with a special emphasis in the developed countries. Several guidelines recognize the role of multimodal therapy consisting of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of pmCRC. New data suggests that some other factors, eg, tumor biology, immune profile, neoadjuvant chemotherapy may play a predictive role for the oncological outcome of these patients.

查看原文本刊更多论文

结直肠癌腹膜癌变：回顾和更新当前的临床数据

腹膜转移性结直肠癌（pmCRC）是全球范围内一个严重的健康问题，发达国家尤其重视这一问题。一些指南认为，由细胞减灭术（CRS）和腹腔热化疗（HIPEC）组成的多模式疗法在治疗 pmCRC 中发挥着重要作用。新的数据表明，肿瘤生物学、免疫状况、新辅助化疗等其他一些因素可能对这些患者的肿瘤预后起着预测作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical colorectal cancer 医学-肿瘤学

CiteScore

5.50

自引率

2.90%

发文量

审稿时长

27 days

期刊介绍： Clinical Colorectal Cancer is a peer-reviewed, quarterly journal that publishes original articles describing various aspects of clinical and translational research of gastrointestinal cancers. Clinical Colorectal Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of colorectal, pancreatic, liver, and other gastrointestinal cancers. The main emphasis is on recent scientific developments in all areas related to gastrointestinal cancers. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.